LLY · NYSE
Eli Lilly
Global pharmaceutical developing peptide-based incretin therapies including tirzepatide and next-generation triagonists.
Overview
Pipeline programs
6Active trials
3Upcoming catalysts
3Indications
4AI research summary
Generated on demand from verified profile data.
Pipeline
Clinical trials
Upcoming catalysts
Timeline
Merged approvals, trial milestones, and catalysts. Newest first.
Nov 08, 2026 · Corporate
Retatrutide Phase 3 interim window
Source ↗Nov 01, 2026 · Trial Milestone
Phase 3 · TRIUMPH — retatrutide obesity program — primary completion (recruiting)
ClinicalTrials.gov ↗Jun 14, 2026 · Corporate
ADA Scientific Sessions
Source ↗Feb 15, 2026 · Corporate
Retatrutide Phase 2 obesity update — guidance window
Source ↗Dec 20, 2024 · Approval
FDA approves Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.
FDA ↗Nov 08, 2023 · Approval
FDA approves Zepbound (tirzepatide) for chronic weight management.
FDA ↗May 13, 2022 · Approval
FDA approves Mounjaro (tirzepatide) for type 2 diabetes.
FDA ↗Apr 01, 2022 · Trial Milestone
Phase 3 · SURMOUNT — tirzepatide in obesity — primary completion (completed)
ClinicalTrials.gov ↗Feb 01, 2021 · Trial Milestone
Phase 3 · SURPASS — tirzepatide in T2D — primary completion (completed)
ClinicalTrials.gov ↗
Verified sources
- [1]Eli Lilly IR — Eli Lilly & Companyretrieved 2026-07-15
- [2]SEC EDGAR — U.S. Securities and Exchange Commissionretrieved 2026-07-15
- [3]FDA — U.S. Food & Drug Administrationretrieved 2026-07-15
- [4]ClinicalTrials.gov — U.S. National Library of Medicineretrieved 2026-07-15
SEC filings search: EDGAR ↗